Vexim Receives The Biotech Future Award ("Prix Biotech d'Avenir") Technology Fast 50 – Southwest Region, From Deloitte In Extenso
Toulouse, November 19, 2013 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announced that its CEO, Vincent Gardès, received the Biotech Future Award (“Prix Biotech d’Avenir”) Southwest Region during the 13th edition of Technology Fast 50 by Deloitte In Extenso, that took place yesterday evening at the Cité de l'Espace in Toulouse, France.
Deloitte's Technology Fast 50 was created by Deloitte France in 2001 and covers all French regions. Each year, it promotes the development of high technology companies that combine growth and innovation. The Prix Biotech d’Avenir (Biotech Award for the Future) recognizes a biotech company with more than three years of existence and having carried out the largest fundraising in its region during 2012.
It is worth noting that VEXIM successfully raised €11 million from its IPO in April 2012. This allowed the company to open two subsidiaries for direct marketing of SpineJack® both in Germany and Italy – the two largest European markets, and to strengthen its management team by hiring managers with a strong experience in medical devices. VEXIM was also granted the NYSE Alternext Award for best IPO of the year at the Stock Market second annual conference in December 2012.
"VEXIM was granted the Prix Biotech d’Avenir (Biotech Award for the Future) by Technology Fast 50 – Southwest Region – for its innovative technology in minimally-invasive back surgery, materialized by SpineJack®, an implant that now allows restoration of the spine following accidental fractures related to osteoporosis, a disease that affects more and more people over 50 years old. It also rewards its successful IPO with its €11 million fundraising in a very difficult market context", said Etienne Alibert, a Deloitte Partner in charge of Deloitte's Technology Fast 50 awards for Southwest France.
"We are delighted to receive this award which recognizes our dynamism and our efforts to become the European leader in minimally-invasive back surgery. I want to thank all our shareholders, especially Truffle Capital for its essential role in our IPO. We also thank Deloitte In Extenso for their support that reinforces SpineJack® as the reference in the treatment of vertebral fractures. Today, we continue our growth strategy based on three pillars: efficient market deployment enhanced clinical program and on-going innovation", said Vincent Gardès, CEO at VEXIM.
The year 2013 was also eventful for VEXIM, which obtained an exclusive worldwide license for an innovative injection device in vertebroplasty, allowing the company to address the vast U.S. market1 as of 2014. VEXIM also created two new subsidiaries in Spain and the UK, expanding its SpineJack® sales network in the 5 major European markets for the treatment of vertebral fractures. Finally, VEXIM has recently unveiled the preliminary results of an international clinical trial involving 103 patients, as well as the final results of a retrospective study regarding 77 patients that confirm the excellent performance of SpineJack® in the treatment of vertebral fractures.
About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital2 and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3rd 2012.
For further information, please go to www.vexim.com
SpineJack®3, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.
Contacts
VEXIM
Vincent Gardès
CEO
Tel: +33 5 61 48 48 38
shareholders@vexim.com
NewCap.
Financial Communications and Investor Relations
Dusan Oresansky /
Emmanuel Huynh
Tel: +33 1 44 71 94 92
vexim@newcap.fr
Alize RP
Press Relations
Caroline Carmagnol
caroline@alizerp.com
Tel: +33 6 64 18 99 59 Christian Berg christian@alizerp.com Tel: +33 1 70 22 53 86
Help employers find you! Check out all the jobs and post your resume.